The incidences of major or nonmajor clinically relevant bleeding with rivaroxaban were not significantly different from those with enoxaparin/VKA , either with ( @ of @,@ , @ % vs. @ of @,@ , @ % ; adjusted HR = @ ; @ % CI = @ to @ ) or without ( @ of @ , @ % vs. @ of @,@ % ; adjusted HR = @ ; @ % CI = @ to @ ; pinteraction = @ ) prestudy heparin .